Behzad Aghazadeh, Director, 10% Owner at Scribe Therapeutics, Inc. (SCTX), bought 2,391,238 shares at $15.00 ($36.3M) on 2026-07-24, disclosed to the SEC on 2026-07-28.
Director Behzad Aghazadeh purchased $35.0 million of Scribe Therapeutics stock at $15.00 per share, marking the largest insider purchase in the company's history. This significant capital commitment suggests high conviction in the company's genetic editing technology and its potential to disrupt cardiovascular treatment.
Scribe shares are currently trading at $18.14, representing a 28.31% discount from the 52-week high of $25.31. The stock has surged 67% since its upsized IPO on July 24, 2026, which valued the company at approximately $440.3 million.
1) Q3 earnings on September 30, 2026; 2) The company raised $125 million in its IPO on July 30, 2026, to fund three clinical trials testing whether its one-time treatments can halve the risk of heart attacks and strokes; 3) Two other insiders bought shares in the last 30 days, indicating a cluster of insider support.
The stock is currently trading 4.46% above its 52-week low of $17.37, meaning there is limited room for error if clinical trial results do not meet expectations.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.00 | 2,333,333 | $35.0M | 96.5% |
| 2 | $22.31 | 50,000 | $1.1M | 3.1% |
| 3 | $18.25 | 7,905 | $144K | 0.4% |
| Total | $15.16 avg | 2,391,238 | $36.3M | 100% |
| Filing → |
| MRTX | SELL | 2019-07-25 | $6.4M | — | Filing → |
| MRTX | SELL | 2019-03-20 | $27.7M | — | Filing → |
| MRTX | SELL | 2019-02-21 | $50.1M | — | Filing → |